Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates
MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer.
SurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2a clinical trial in adults with newly diagnosed glioblastoma.
Additional indications are being evaluated through:
- Phase 1 clinical trials in multiple myeloma combination with REVLIMID® (lenalidomide)
- Phase 1 in Neuro-Endocrine Tumors (NET)
- Pilot Study in Pediatric High Grade Glioma, recurrent/relapsed Medulloblastoma and DIPG
Company Details
- Employees
- 3
- Founded
- 2012
- Address
- Elm & Carlton Streets, Buffalo,ny 14263,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.mimivax.com
- HQ
- Buffalo, NY
Mimivax, Inc. Questions
Mimivax, Inc.'s website is http://www.mimivax.com
Mimivax, Inc.'s LinkedIn profile is https://www.linkedin.com/company/mimivax
Mimivax, Inc. has
3 employees.
View email and phone details for 3
employees at Mimivax, Inc..
Mimivax, Inc.'s industry is
Biotechnology Research
Mimivax, Inc.'s top competitors are
Brain Tumor Investment Fund,
Roswell Park Comprehensive Cancer Center,
Chimerix, A Jazz Pharmaceuticals Company,
Trutino Biosciences,
National Brain Tumor Society,
Kiyatec Inc.,
University Of Iowa Pharmaceuticals,
Morphic Therapeutic,
Athenex,
Medicenna Therapeutics Corp..
Mimivax, Inc.'s categories are Biotechnology Research
Mimivax, Inc.'s founding year is 2012
